RVL Pharmaceuticals plc CEO Brian Markison's 2020 pay slips 12% to $3.8M
RVL Pharmaceuticals plc reports 2020 executive compensation
By ExecPay News
Published: April 26, 2021
RVL Pharmaceuticals plc reported fiscal year 2020 executive compensation information on April 26, 2021.
In 2020, four executives at RVL Pharmaceuticals plc received on average a compensation package of $1.9M, a 12% decrease compared to previous year.
Average pay of disclosed executives at RVL Pharmaceuticals plc
Brian Markison, Chief Executive Officer, received $3.8M in total, which decreased by 12% compared to 2019. 63% of Markison's compensation, or $2.4M, was in stock awards. Markison also received $690K in non-equity incentive plan and $716K in salary.
James Schaub, Chief Operating Officer, received a compensation package of $1.3M, which decreased by 11% compared to previous year. 50% of the compensation package, or $670K, was in stock awards.
Tina deVries, EVP, Research Development, earned $1.3M in 2020, a 13% decrease compared to previous year.
Christopher Klein, General Counsel, received $1.3M in 2020, which decreases by 13% compared to 2019.
Related executives
You may also like
Source: SEC filing on April 26, 2021.